PMID: 9420288Jan 7, 1998Paper

Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma

Journal of Virology
R M DiazR G Vile

Abstract

To generate transcriptionally targeted vectors, tissue-specific elements of the human tyrosinase promoter were exchanged with corresponding viral elements in the Moloney murine leukemia virus long terminal repeat (LTR). From these experiments, a vesicular stomatitis virus type G pseudotyped, hybrid LTR vector that contained three tyrosinase enhancer elements and gave high-level, tightly tissue-specific expression at high titers (3 x 10(7) CFU/ml) was constructed.

References

Jan 1, 1992·Annual Review of Cell Biology·J M Whitcomb, S H Hughes
Feb 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·T D PalmerA D Miller
Jan 1, 1990·Current Topics in Microbiology and Immunology·J Majors
Feb 1, 1989·Molecular and Cellular Biology·J R FlanaganA S Khan
May 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·S F YuE Gilboa
Sep 1, 1995·Nature Medicine·C Wilson, M A Kay
Jan 1, 1995·British Medical Bulletin·R G Vile, S J Russell
Feb 1, 1995·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·N Miller, R Vile
May 10, 1994·Proceedings of the National Academy of Sciences of the United States of America·Y YangJ M Wilson
Oct 15, 1996·Proceedings of the National Academy of Sciences of the United States of America·D S OryR C Mulligan
Dec 1, 1996·Molecular Biotechnology·W Walther, U Stein

❮ Previous
Next ❯

Citations

Feb 24, 2001·The Journal of Gene Medicine·P Y Lam, X O Breakefield
Nov 20, 2002·Journal of Virology·Christopher R LoggNoriyuki Kasahara
Jun 8, 2004·Pediatric Research·Sabine SteffensChristof M Kramm
Dec 29, 2004·FEBS Letters·Rosanna Martinelli, Vincenzo De Simone
Aug 10, 2004·Nature Biotechnology·Gregory A DanielsRichard G Vile
Oct 1, 2020·Viruses·Aneta PlutaRenée N Douville
Sep 12, 2002·Gene Therapy·S GhazizadehL B Taichman
Oct 18, 2005·Journal of Cellular Biochemistry·Daniel J Selski, Denis R Clohisy
Nov 5, 2002·The Journal of Clinical Endocrinology and Metabolism·Luisa BarzonGiorgio Palù
Dec 20, 2005·The Journal of Pathology·Lawrence S YoungVivien Mautner
May 23, 2006·Pharmaceutical Research·Ethlinn V B van GaalEnrico Mastrobattista
Dec 19, 2002·Cancer Gene Therapy·Sounkary K SollyDavid Klatzmann
Jan 2, 2021·Pathogens·Aneta PlutaCésar N Cortés-Rubio
Dec 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kei HiraokaNoriyuki Kasahara
Feb 24, 2001·The Journal of Gene Medicine·J C Zhao-EmonetD Klatzmann
May 18, 2000·Reviews in Medical Virology·G PalùM Pizzato
Nov 18, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·G Daly, Y Chernajovsky
Nov 10, 2000·Advanced Drug Delivery Reviews·K J HarringtonR G Vile
May 3, 2000·Kidney International·V Kon, I Ichikawa
May 26, 2005·Biochimica Et Biophysica Acta·G D HallJ D Chester

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.